Navigation Links
Vaccine has cut child cases of bacterial pneumonia, says study
Date:8/26/2010

The number of children admitted to English hospitals with bacterial pneumonia decreased by a fifth in the two years following the introduction of a vaccine to combat the disease, according to a new study published today in the journal Thorax.

Bacterial pneumonia is a serious illness caused by Streptococcus pneumoniae bacteria that mostly affects babies, young children and elderly people. In Europe, around one in ten deaths in the under-fives is caused by the disease.

Bacterial pneumonia usually develops as a complication following a respiratory tract infection such as influenza. Symptoms include difficulty breathing, wheezing, fever and loss of appetite.

In September 2006, a vaccine known as PCV7 was introduced into the childhood primary immunisation programme across the UK, to protect against seven different strains of Streptococcus pneumoniae bacteria.

Today's study, led by researchers from Imperial College London, shows that in the first two years following the introduction of this vaccine, hospital admissions for bacterial pneumonia decreased by 19 per cent amongst children aged under 15 years. Admissions for empyema, a rare and serious complication of bacterial pneumonia, decreased by 22 per cent.

The pneumococcal vaccine is administered at two, three and 13 months of age. When it was first introduced there was a catch-up campaign for children up to two years. Take-up of the vaccine over the study period was high. It was administered to an average of 84 per cent of eligible children in England in the first year following its introduction and 91 per cent the following year.

Dr Sonia Saxena, who led the study from the School of Public Health at Imperial College London and works as a GP in South London, said: "It's a frightening experience for everyone involved when your child becomes unwell and very disruptive to families if they need to be admitted to hospital, so we're really pleased that the number of children becoming seriously unwell and needing admission to hospital with bacterial pneumonia and empyema has fallen since the vaccination programme was introduced. In addition, it's great that such a large proportion of parents chose to have their child vaccinated over the period we were studying. The success of any vaccination programme depends on vaccinating as many people as possible. Now that we have clear evidence about the benefits of the pneumonia vaccine, we hope more parents will be encouraged to have their children vaccinated in future."

The study showed that the number of older children admitted with bacterial pneumonia decreased, as well as the number of younger children, following introduction of the vaccine. This result suggests that vaccinating young children against bacterial pneumonia also provides protection for older, non-vaccinated children, providing 'herd immunity' by slowing the spread of disease.

The PCV7 vaccine was introduced in England after hospital admission rates for bacterial pneumonia and empyema increased by 31 per cent and 260 per cent respectively, between 1997 and 2006, amongst children aged under 15 years. The reasons for this increase are unclear. Prior to the introduction of PCV7, there were 13,771 hospital admissions for bacterial pneumonia among children under 15 years in 2005.

The PCV7 vaccine has now been replaced with a newer pneumococcal vaccine called PCV13, which works in the same way as PCV7 but protects against more strains of Streptococcus pneumoniae bacteria. There are around 90 strains of this bacteria and around a quarter of cases are caused by strains not covered by PCV13.

Joanna Murray, a co-author of the study, also from the School of Public Health at Imperial College London, added: "Our study looked at a two year period since the introduction of PCV7. We are keen to see whether there continues to be a decrease in the number of cases, which is what we are hoping. Our results are encouraging, but even with a vaccination programme in place bacterial pneumonia remains an important cause of morbidity and mortality among children. Scientists are working to develop even better vaccines that can protect against more strains of Streptococcus pneumoniae bacteria and protect even more people."

The study was funded by the National Institute for Health Research, the Medical Research Council and the Engineering and Physical Sciences Research Council.


'/>"/>

Contact: Sam Wong
sam.wong@imperial.ac.uk
44-207-594-2198
Imperial College London
Source:Eurekalert

Related medicine news :

1. Mumps vaccine coverage should be improved, study finds
2. Survey of American women finds STD vaccine viewed positively
3. More U.S. Teens Get Recommended Vaccines
4. New human adenovirus may not make for good vaccines, after all
5. Human clinical trial of NIH-developed dengue vaccine begins
6. UR discovers new way to boost vaccines, seeks patent
7. Alphavirus-based vaccine may slow some cancers
8. Boosting the efficacy of anticancer vaccines
9. Vaccine Shows Some Promise Against Advanced Cancers
10. H1N1 Protection in Coming Seasons Flu Vaccines: FDA
11. Small increases in vaccine cost can cause large gaps in protection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme ... on Sunday, with sunny skies, a light breeze and temperatures in the 60s. Over ... The 5k Run and Walk and 1-mile walk were held to increase awareness ...
(Date:4/29/2016)... Fla. (PRWEB) , ... April 29, 2016 , ... ... Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have better ... is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton School ... Perlman Grand Prize of the 2016 Wharton Business Plan Competition —as well ... Choice Award, and the Committee Award for Most ‘Wow Factor,’ making them the ...
(Date:4/29/2016)... ... April 29, 2016 , ... World Patent Marketing , ... exercise invention which aids in proper muscle development. , "The Gym & Exercise ... Director of World Patent Marketing. "Globalization has threatened the future growth of the ...
(Date:4/29/2016)... ... 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 ... skin cancer deaths. More than 10,000 people are expected to die of melanoma this year. ... is the one of the most commonly diagnosed cancers in young women. A recent breakthrough ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 Dr. Vivek Ahuja , ... Ste phen Schmidt ... provider of cloud-based software solutions for life sciences, today announced key ... a wealth of insight to a growing business.  This will bolster ... George Phillips joined ArisGlobal in the position of Vice ...
(Date:4/28/2016)... JACKSONVILLE, Florida , April 28, 2016 ... in the development of innovative peptide and gene-based immunotherapeutics and ... announced it will be presenting at the 3rd Annual ... - 5 th , 2016 at Caesars Palace in Las ... at 8.00 am on Wednesday, May 4 th by ...
(Date:4/27/2016)...   , ... le trimestre, soutenu par une croissance de +42% ... de +16% des ventes aux hôpitaux et cliniques  ... (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de Cellvizio®, ... chiffre d,affaires pour le premier trimestre clos au ...
Breaking Medicine Technology: